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Abstract
The P2Y14 receptor is a G protein-coupled receptor activated by uridine-5′-diphosphoglucose and
other nucleotide sugars that modulates immune function. Covalent conjugation of P2Y14 receptor
agonists to PAMAM (polyamidoamine) dendrimers enhanced pharmacological activity.
Uridine-5′-diphosphoglucuronic acid (UDPGA) and its ethylenediamine adduct were suitable
functionalized congeners for coupling to several generations (G2.5–6) of dendrimers (both
terminal carboxy and amino). Prosthetic groups, including biotin for avidin complexation, a
chelating group for metal complexation (and eventual magnetic resonance imaging), and a
fluorescent moiety, also were attached with the eventual goals of molecular detection and
characterization of the P2Y14 receptor. The activities of conjugates were assayed in HEK293 cells
stably expressing the human P2Y14 receptor. A G3 PAMAM conjugate containing 20 bound
nucleotide moieties (UDPGA) was 100-fold more potent (EC50 2.4 nM) than the native agonist
uridine-5′-diphosphoglucose. A molecular model of this conjugate docked in the human P2Y14
receptor showed that the nucleotide-substituted branches could extend far beyond the dimensions
of the receptor and be available for multivalent docking to receptor aggregates. Larger dendrimer
carriers and greater loading favored higher potency. A similar conjugate of G6 with 147 out of 256
amino groups substituted with UDPGA displayed an EC50 value of 0.8 nM. Thus, biological
activity was either retained or dramatically enhanced in the multivalent dendrimer conjugates in
comparison with monomeric P2Y14 receptor agonists, depending on size, degree of substitution,
terminal functionality, and attached prosthetic groups.
Introduction
G protein-coupled receptors (GPCRs)1 are cell membrane-spanning receptors that respond
to extracellular signaling molecules to control cell function via specific signaling pathways.
Direct or indirect modulation of GPCRs serves as the basis of many disease treatments (1).
The P2 receptors for purine and pyrimidine nucleotides have diverse biological roles (2–4).
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P2 receptors are divided into two structurally unrelated subfamilies–the P2X receptors,
which are ligand-gated ion channels (5), and the P2Y receptors (2), which are GPCRs. P2Y
receptors are divided into two subgroups. The first subgroup consisting of the P2Y1, P2Y2,
P2Y4, P2Y6, and P2Y11 receptors activate Gq and promote phospholipase C (PLC)-
dependent inositol lipid signaling. The second consists of P2Y12, P2Y13, and P2Y14
receptors, which preferentially activate Gi and inhibit adenylyl cyclase (2). P2Y receptors
are activated by adenine and/or uracil nucleotides, while P2X receptors are principally
activated by adenine nucleotides. P2Y receptors are widely distributed, for example, in the
immune system (and widely distributed on hematopoietic cells), cardiovascular system,
central and peripheral nervous system, endocrine system, and the renal and pulmonary
systems (3–10).
The P2Y14 receptor is activated by uridine-5′-diphosphoglucose (UDPG) 1 (Chart 1) and
other UDP-sugars (11, 12). The P2Y14 receptor affects immune function, but the
physiological function of the receptor is not clearly established (13, 14). Extracellular 1 also
acts as a weak full agonist at the P2Y2 receptor (EC50 10 μM) (15). We have studied the
SAR of nucleotide derivatives at this receptor, which is among the most structurally
restrictive of the P2Y family (15–18). Activity of synthetic analogues of 1 at the P2Y14
receptor has been followed through the stimulation of phosphoinositide hydrolysis by
coexpression in COS-7 cells of a PLC-activating chimeric G protein that responds to Gi-
coupled receptors (18).
Dendrimers are tree-like polymeric macromolecular nanostructures,which can serve as
nanocarriers for drug delivery (19–21). Dendrimer chemistry offers versatility in the control
of the component functional groups and in feasibility for conjugation of multiple functional
units at both the periphery and interior. Dendrimers recently have attracted considerable
attention in biomedical research in the context of drug delivery (targeted/ controlled release,
encapsulation, or covalent/electrostatic attachment) (22–24), protein–carbohydrate
interactions (multivalent effect) (25–30), medical diagnostics (signal amplification) (31, 32),
and tissue engineering (33, 34).
Polyamidoamine (PAMAM) dendrimers have well-defined chemical structures in which a
core is surrounded by successively added (and bifurcating) layers of methyl acrylate and
ethylenediamine, which form each dendrimeric shell (or “generation”) of the polymer.
Different generations of PAMAM dendrimers have either primary amine (integral
generations) or carboxylic acid (half-integral generations) groups on their surface, and the
number of surface groups for conjugation to multiple functional units depends on the
generation of the dendrimer. PAMAM dendrimers are relatively biocompatible, which
allows many applications in biomedicine (35–38).
We recently reported the first example of application of dendrimers to multivalent GPCR-
promoted signal transduction in a study of adenosine receptor-targeted dendrimers (39–41).
Various adenosine receptor agonists were attached covalently to PAMAM dendrimers, and
the resulting nucleoside conjugates displayed distinct biological properties, including potent
inhibition of platelet aggregation.
Here, we report the first example of application of PAMAM dendrimers to covalently
conjugate a P2Y receptor ligand resulting in the enhancement of its pharmacological
1Abbreviations: DTPA, diethylenetriaminepentaacetic acid; EDC, N-ethyl-N′-dimethylaminopropylcarbodiimide; GPCR, G protein-
coupled receptor; HEK, human embryonic kidney; IBMX, 3-isobutyl-1-methylxanthine; MES, 2-(N-morpholino)ethanesulfonic acid;
MRI, magnetic resonance imaging; NHS, N′-hydroxysuccinimide; PAMAM, polyamidoamine; SAR, structure activity relationship; p-
SCN-Bn-DTPA, 2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid; UDPG, uridine-5′-diphosphoglucose; UDPGA,
uridine-5′-diphosphoglucuronic acid.
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activity. The P2Y14 receptor agonist uridine-5′-diphosphoglucuronic acid (UDPGA) 2 and
its ethylenediamine adduct 3a were utilized as appropriately functionalized congeners to
couple with several generations of PAMAM dendrimers with the goal of modulating
pharmacological interaction with this receptor. We also attached prosthetic groups, such as
biotin, AlexaFluor488, and the metal chelating group diethylenetriaminepentaacetic acid
(DTPA) on the dendrimer-nucleotide conjugates for targeting the P2Y14 receptor in vivo.
Our long-term goal is to initiate the genesis of receptor probes that lead to improved
biomedical diagnostics and possibly to novel conjugates for drug treatment.
Experimental Procedures
Chemical Synthesis
Materials and Methods—All reactions were carried out under a nitrogen atmosphere.
G2.5 PAMAM (10 wt % solution in methanol), G3 PAMAM (20 wt % solution in
methanol), G5.5 PAMAM (5 wt % solution in methanol), and G6 PAMAM (5 wt % solution
in methanol), dendrimer with an ethylenediamine core, EDC, UDPGA, Gd(OAc)3, and
ethylenediamine were purchased from Aldrich. Sulfo-NHS-LC-biotin was purchased from
Pierce (Rockford, IL), and Alex-aFluor488-carboxylic acid 2,3,5,6-tetrafluorophenyl ester
(AlexaFluor488–5-TFP) was purchased from Invitrogen Corp. (Carlsbad, CA) and 2-(4-
isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid (p-SCN-Bn-DTPA) purchased
from Macrocyclic (Dallas, TX). Dialysis membranes (Spectra/Pore Membrane, MWCO
3500, flat width 18 mm) were purchased from Spectrum Laboratories, Inc. (Rancho
Dominguez, CA).
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker DRX-600
spectrometer using D2O as a solvent. The chemical shifts are expressed as relative ppm from
HOD (4.80).
The electrospray ionization mass spectrometry (ESI MS) and matrix-assisted laser
desorption ionization time-of-flight (MALDI-TOF) MS experiments were performed on a
Waters LCT Premier mass spectrometer at the Mass Spectrometry Facility, NIDDK, NIH.
Synthesis of G3 or G6 PAMAM-UDPGA Conjugates 8, 9, and 12—A commercial
solution of G3 PAMAM 5 (100 μL, 2 μmol) or G6 PAMAM 7 (167 μL, 0.11 μmol) was
added to a round-bottom flask, and the methanol was evaporated using a rotary evaporator.
The dendrimer was treated with EDC-HCl (2.1 mg, 5.5 equiv for compound 8; 13.8 mg, 36
equiv for compound 9; and 5.4 mg, 256 equiv for compound 12) and then dissolved with
minimum volume of 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES), pH 5 (1 mL). The
reaction mixture was stirred and UDPGA 2 (7.7 mg, 6 equiv for compound 8; 82.7 mg, 64
equiv for compound 9; and 27.2 mg, 384 equiv for compound 12) was added. The pH of the
reaction was adjusted to the range 4.5–5.0 using 0.1 M HCl. The reaction mixture was
stirred at room temperature under nitrogen atmosphere for 2 days and then diluted with
water (1 mL). After that, the product was purified by extensive dialysis in water. The
mixture was then lyophilized to give the pure product of the conjugates 8, 9, and 12.
G3 PAMAM-UDPGA Conjugate 8 (Low Loading)—Compound 8 (13.5 mg, 71%) was
obtained as a white solid following the general procedure. The product was analyzed by
NMR and MALDI-TOFF MS, which indicated approximately 4.3 UDPGA moieties
attached per dendrimer. 1H NMR (D2O) δ 7.84 (d, J = 8.8 Hz, 4.3 H), 5.91 (d, J = 5.7 Hz,
8.6 H), 5.53 (m, 4.3 H), 4.28 (m, 8.6 H), 4.17 (m, 8.6 H), 4.08 (m, 8.6 H), 3.85 (m, 4.3 H),
3.63 (m, 8.6 H), 3.44 (m, 180 H), 3.3 (m, 120 H), 3.14 (m, 60 H), 2.72 (m, 120 H); m/z
(M +ESI MS) found 9848.0; calc 9519.0.
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G3 PAMAM-UDPGA Conjugate 9 (High Loading)—Compound 9 (26 mg, 68%) was
obtained as a white solid following the general procedure. The product was analyzed by
NMR and MALDI-TOFF MS, which indicated approximately 20.1 UD-PGA moieties
attached per dendrimer.1H NMR (D2O) δ 7.88 (d, J = 7.4 Hz, 20.1 H), 5.81 (d, J = 5.4 Hz,
40.2 H), 5.51 (dd, J = 3.3, 6.1 Hz, 20.1 H), 4.3 (m, 40.2 H), 4.2 (m, 40.2 H), 4.1 (m, 40.2 H),
3.65 (m, 20.1 H), 3.52 (m, 40.2 H), 3.41 (m, 180 H), 3.3 (m, 120 H), 3.14 (m, 60 H), 2.72
(m, 120 H); m/z (M +ESI MS) found 18721.4; calc 19113.7.
G6 PAMAM-UDPGA Conjugate 12—Compound 12 (9.86 mg, 61%) was obtained as a
white solid following the general procedure. The product was analyzed by NMR and
MALDI-TOFF MS, which indicated approximately 147 UDPGA moieties attached per
dendrimer. 1H NMR (D2O) δ 7.87 (d, J = 7.5 Hz, 147 H), 5.89 (d, J = 5.4 Hz, 294 H), 5.51
(m, 147 H), 4.29 (m, 294 H), 4.17 (m, 294 H), 4.09 (m, 294 H), 3.81 (m, 147 H), 3.7 (m, 294
H), 3.51 (m, 512 H), 3.41 (m, 512 H), 3.28 (m, 1020 H) 3.12 (m, 504 H), 3.07 (m, 504 H),
2.78 (m, 1020 H). The molecular weight was unable to be determined using ESI or MALDI-
TOF MS, possibly due to stacking of the PAMAM dendrimer or because of the high
molecular weight.
Synthesis of G2.5 or G5.5 PAMAM–UDPGA Conjugates 10 and 11—A
commercial solution of G2.5 PAMAM 4 (13.76 μL, 0.2 μmol) or G5.5 PAMAM 6 (115 μL,
0.1 μmol) was added to a round-bottom flask, and the methanol was evaporated. EDC-HCl
(1.4 mg, 36 equiv, for compound 8; and 1.9 mg, 100 equiv for compound 9) was added to
the residue, and then the mixture was dissolved in a minimum volume of 0.1 M MES, pH 5
(0.5 mL), and stirred under a nitrogen atmosphere. UDPGA-ethylenediamine (3a) was
added to the reaction mixture (6.5 mg, 50 equiv, for compound 10; and 13.1 mg, 200 equiv,
for compound 11). The pH of the reaction mixture was maintained within the range 4.5–5.0
using 0.1 M HCl. After 48 h, the small molecule impurities were removed by extensive
dialysis in water. After dialysis, the mixture was lyophilized to give conjugate 10 or 11.
G2.5 PAMAM-UDPGA Conjugate 10—Compound 10 (2.4 mg, 66%) was obtained as a
white solid following the general procedure. The product was analyzed by NMR and
MALDI-TOF MS, which indicated approximately 17.3 UDPGA moieties attached per
dendrimer. 1H NMR (D2O) δ 7.82 (d, J = 7.7 Hz, 17.34 H), 5.84 (d, J = 5.5 Hz, 34.68 H),
5.51 (dd, J = 3, 5.1 Hz, 17.34 H), 4.29 (m, 52.0 H), 4.15 (m, 52.0 H), 3.7 (m, 17.34 H), 3.51
(m, 98.7 H), 3.41 (m, 120 H), 3.31 (m, 90.7 H), 3.14 (m, 60 H), 2.68 (m, 34.7 H), 2.51 (m,
56 H); m/z (M +ESI MS) found 18151.4, calc 18477.9.
G5.5 PAMAM-UDPGA Conjugate 11—Compound 11 (4.5 mg, 63%) was obtained as a
white solid following the general procedure. The product was analyzed by NMR and
MALDI-TOF MS, which indicated approximately 29.9 UDPGA moieties attached per G5.5
dendrimer. 1H NMR (D2O) δ 7.85 (d, J = 8.3 Hz, 29.94 H), 5.88 (d, J = 6.5 Hz, 59.9 H),
5.57 (dd, J = 3.1, 5.7 Hz, 29.9 H), 4.26 (m, 89.8 H), 4.14 (m, 89.8 H), 3.72 (m, 29.94 H),
3.44 (m, 571 H), 3.23 (m, 1075.88 H), 2.84 (m, 504 H), 2.67 (m, 508 H), 2.48 (m, 564 H);
m/z (M +ESI MS) found 72626, calc 71651.
Synthesis of G3 PAMAM-UDPGA-Biotin Conjugate 13—A mixture of G3 PAMAM
complex 9 (20 mg, 1.04 μmol) and Sulfo-NHS-LC-Biotin 17 (361 μg, 0.65 μmol) in a flask
was dissolved in bicarbonate buffer (1 mL, pH 8.5, 0.002 M Na2CO3, 0.048 M NaHCO3,
0.15 M NaCl). After 48 h of stirring at room temperature, the reaction mixture was diluted
with 1 mL water, and the product was purified by dialysis against water. The solution was
then lyophilized, which provided G3 PAMAMbotin 13 (14.4 mg, 67%) as a white solid. The
product was analyzed by NMR and MALDI-TOF MS, which indicated that approximately
Das et al. Page 4













4.87 biotin moieties attached per dendrimer. 1H NMR (D2O) δ 7.87 (d, J = 7.4 Hz, 20.1 H),
5.82 (d, J = 5.4 Hz, 40.2 H), 5.51 (m 20.1 H),4.55 (m, 9.74 H) 4.28 (m, 40.2 H), 4.18 (m,
40.2 H), 4.09 (m, 40.2 H), 3.67 (m, 20.1 H), 3.53 (m, 40.2 H), 3.42 (m, 180 H), 3.28 (m, 135
H), 3.11 (m, 60 H), 2.91(m, 9.74 H) 2.71 (m, 120 H), 2.12 (m, 19.5 H), 1.52 (m, 39.0 H),
1.27 (m, 19.5 H); m/z (M +ESI MS) found 21114.0, calc 20767.0.
Synthesis of G3 PAMAM-UDPGA-AlexaFluor488 Conjugate 14—G3 PAMAM
complex 9 (20 mg, 1.04 μmol) was reacted with AlexaFluor488-5-TFP 18 (575 μg, 0.65
μmol) in bicarbonate buffer (1 mL, pH 8.5, 0.002 M Na2CO3, 0.048 M NaHCO3, 0.15 M
NaCl). The reaction mixture was stirred for 2 days at room temperature and then diluted
with 1 mL of water. The mixture was purified by dialysis with water. Lyophilization of the
solution gave the G3 PAMAM–AlexaFluor488 complex 14 (13.4 mg, 62%) as a red solid.
The product was analyzed by NMR and MALDI-TOFF MS, which indicated approximately
2.3 AlexaFluor488 moieties attached per dendrimer. 1H NMR (D2O) δ 8.28 (m, 2.3 H), 8.01
(d, J = 7.4 Hz, 20.1 H), 7.85 (m, 4.6 H), 6.1 (m, 2.3 H), 6.9 (m, 2.3 H), 5.9 (d, J = 5.4 Hz,
40.2 H), 5.75 (m, 2.3 H), 5.53 (dd, J = 3.1, 5.9 Hz, 20.1 H), 5.3 (m, 2.3 H), 4.32 (m, 40.2 H),
4.21 (m, 40.2 H), 4.18 (m, 40.2 H), 3.94 (m, 40.2 H), 3.68 (m, 20.1 H), 3.43 (m, 180 H),
3.28 (m, 120 H), 3.15 (m, 60 H), 2.63 (m, 120 H); m/z (M +ESI MS) found 22336.0, calc
20766.3.
Synthesis of G3 PAMAM-UDPGA-DTPA Conjugate 15 and G3 PAMAM-UDPGA-
DTPA-Gd Conjugate 16—G3 PAM-AM complex 9 (20 mg, 1.04 μmol) was stirred with
p-SCN-Bn-DTPA 19 (351 μg, 0.65 μmol) in bicarbonate buffer (1 mL, pH 8.5, 0.002 M
Na2CO3, 0.048 M NaHCO3, 0.15 M NaCl). The reaction mixture was stirred for 48 h, at
room temperature, and then the small molecule impurities were removed by extensive
dialysis in water followed by lyophilization to yield the G3 PAMAM-DTPA complex 15
(15.2 mg, 68%) as a white solid. The product was analyzed by NMR and MALDI-TOF MS,
which indicated approximately 4.5 DTPA moieties attached per dendrimer. 1H NMR (D2O)
δ 7.89 (d, J = 7.4 Hz, 20.1 H), 7.21 (m, 9 H), 7.31 (m, 9 H), 5.85 (d, J = 5.4 Hz, 40.2 H),
5.53 (dd, J = 3.3, 6.1 Hz, 20.1 H), 4.31 (m, 40.2 H), 4.24 (m, 40.2 H), 4.15 (m, 80.4 H), 3.71
(m, 20.1 H), 3.64 (m, 49.5 H), 3.44 (m, 180 H), 3.33 (m, 120 H), 3.16 (m, 69 H), 2.63 (m,
120 H), 2.66 (m, 27 H); m/z (M +ESI MS) found 22744.0, calc 21546.1.
The chelating prosthetic group on conjugate 15 was used to complex Gd(III) by addition of
Gd(OAc)3. G3 PAMAM-UDPGA-DTPA 15 (10 mg, 0.46 μmol), Gd (OAc)2 (94 μg, 0.28
μmol) were dissolved in 0.3 M citrate buffer (1 mL, pH 4.5). The mixture was stirred at
room temperature for 48 h in dark. The mixture was dialyzed sequentially with 0.1 M
NH4OAc (pH 7.0) to remove the uncomplexed Gd(III) and then extensively against water.
Lyophilization of the solution gave the product 16 (7.5 mg, 74%). Since the compound 16
contains Gd(III), we could not analyze the NMR spectra. We assume that all the DTPA
moieties would complex with Gd(III), because we reacted 15 with excess Gd(OAC)3 in this
theoretically quantitative reaction. So, we assumed that compound G3 PAMAM-UDPGA-
DTPA-Gd(III) 16 contained approximately 4.5 Gd(III) moieties attached per dendrimer
based on the stoichiometry of the precursor, which was comparable to mass spectral data. m/
z (M +ESI MS) found 24175.0, calc 22311.2.
Biological Methods
Materials—IBMX was purchased from SigmaAldrich (St. Louis, MO). Compounds 1 and
2 were manufactured by Fluka and were purchased from SigmaAldrich (St. Louis, MO).
[3H]Adenine was purchased from American Radiolabeled Chemicals (St. Louis, MO). All
cell culture media and sera were from Gibco (Invitrogen, Carlsbad, CA).
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Cell Culture—Human embryonic kidney-293 cells stably expressing the human P2Y14-R
(P2Y14–HEK293 cells) were generated as previously described by Fricks et al. (46). P2Y14–
HEK293 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 1% genticin (Gibco), and 1% antibiotic–antimocotic
(Gibco) at 37 °C in a 5% CO2 environment.
Cyclic AMP Accumulation—P2Y14–HEK293 cells were grown in 24-well plates and
incubated with 1 μCi [3H]adenine/well in serum-free DMEM for at least 2 h prior to assay.
Assays were initiated by addition of HEPES-buffered, serum-free DMEM containing 200
μM 3-isobutyl-1-methyl-xanthine (IBMX) and 30 μM forskolin, with or without drugs, and
incubation continued for 15 min at 37 °C. Incubations were terminated by aspiration of the
medium and addition of 450 μL ice-cold 5% trichloroacetic acid. [3H]Cyclic AMP was
isolated by sequential Dowex and alumina chromatography and quantified by liquid
scintillation counting as previously described by Harden et al. (55).
Data Analysis—The concentrations of the dendrimer–ligand complexes were measured by
the concentration of the dendrimer, not the attached ligand. EC50 values were determined
using Prism software (GraphPad, San Diego, CA) and are presented as mean ± SE. All
experiments were repeated at least three times.
Results
Chemical Synthesis
We recently investigated the SAR (structure–activity relationship) of analogues of UDPG 1
at the P2Y14 receptor (15, 16), but few of the ligands displayed comparable pharmacological
properties to those of the native ligand, and nearly all modifications of the uracil and ribose
moieties abolished activity. We also reported that functionalized congeners of UDPGA 2 in
which an amide-linked chain was extended from the terminal carboxylic acid group via N-
acetylethylenediamine (e.g., 3b) or N-(t-butyloxycarbonyl)ethylenediamine moieties did not
significantly differ from 1 in their pharmacological activity (15). This suggests that it is
possible to incorporate structural modifications of the carboxylic acid chain in 2 that do not
substantively affect interaction with the P2Y14 receptor.
In this study, we first coupled 2 with the peripheral amino groups of a third-generation (G3)
PAMAM dendrimer to yield 8 and 9 and to a sixth-generation (G6) PAMAM dendrimer to
yield 12. The coupling conditions used were the water-soluble carbodiimide reagent EDC in
aqueous medium at pH 4.5 in 0.1 M MES buffer and under a nitrogen atmosphere (Scheme
1). The degree of substitution of the G3 dendrimer was varied to determine how the fraction
of drug loading on the PAMAM surface would affect the pharmacological activity.
Compound 8 contained an average of 4.3 bound nucleotide moieties (2) per dendrimer, and
compound 9 an average of 20.1 bound nucleotide moieties per dendrimer, out of a
theoretical 32. The degree of substitution was calculated using mass spectroscopy and
integration of the 600 MHz 1H NMR spectra. For compound 12, we added excess nucleotide
monomer to derivatize the maximum number of nucleotide moieties on the surface of a G6
dendrimer, in which the average number of drug moieties attached was found to be an
average of 147 out of a theoretical 256. Following the coupling reaction, we removed all
residual compound 2 that remained unreacted by extensive dialysis in water. Thus, we
successively varied the number of covalently attached ligands, determined to be an average
of 4.3, 20.1, and 147 per dendrimer in compounds 8, 9, and 12, respectively.
A G3 PAMAM-biotin conjugated UDPGA complex 13 also was prepared. Since biotin and
its amide derivatives are known to bind strongly with the tetrameric protein avidin,
compound 13 was designed as a multifunctional chemical probe of the P2Y14 receptor. For
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the preparation of compound 13, PAMAM-UDPGA 9 was reacted with a water-soluble N-
hydroxysuccinimide (NHS) ester of a chain-elongated biotin 17 in bicarbonate buffer at pH
8.5 (Scheme 2) and the product 13 was subjected to dialysis in water. From the 1H NMR and
mass spectra, we confirmed that the average number of biotin units attached in compound 13
was 4.9 per dendrimer.
With the eventual goal of direct microscopic visualization of the P2Y14 receptor in
biological systems, we prepared a fluorescent dendrimer–UDPGA derivative 14. Compound
14 was synthesized by reaction of 9 and an equimolar amount of 5-carboxy
tetrafluorophenyl ester of AlexaFluor488 18 in the presence of triethylamine in a minimum
volume of water. AlexaFluor488 was chosen, because although its fluorescent properties are
similar to fluorescein, it exhibits higher photostability, pH insensitivity, and good water
solubility (42). We subjected compound 14 to dialysis in water to remove low MW
impurities. The conjugated product was analyzed by 1H NMR and mass spectroscopy, which
showed that the average number of AlexaFluor488 units attached per dendrimer molecule
was 2.3.
PAMAM dendrimers recently were used for magnetic resonance imaging (MRI) (43). MRI
is one of the fastest growing diagnostic methods in medical technology because of its
effectiveness in visualizing soft tissues with good resolution. Ionic gadolinium is a widely
used reagent for MRI, and a chelated Gd(III) complex recently was covalently attached to
PAMAM dendrimers for molecular imaging (44). As such, we derivatized the PAMAM–
UDPGA conjugate 9 with the same MRI-active reagent for chelation of Gd(III). Compound
9 was reacted with an electrophilic reactive derivative (aryl isothiocyanate) of
diethylenetriaminepentaacetic acid (DTPA) 19 in bicarbonate buffer at pH = 8.5 for two
days to obtain compound 15, which was purified by dialysis in water. The molecular weight
of 15 was >10 000 D, and 1H NMR and mass spectroscopic analyses revealed that the
average number of DTPA moieties attached in compound 15 was 4.5 per dendrimer. We
subsequently reacted compound 15 with excess Gd(OAc)3 in the presence of 0.3 M citrate
buffer (pH = 4.5) to obtain compound 16, which was subjected to dialysis using 0.1 M
ammonium acetate to remove low MW impurities. It was not possible to obtain a 1H NMR
spectrum for compound 16, so we have assumed that the number of Gd(III) ions in
compound 16 was 4.5 based on quantitative complexation of the attached DTPA with excess
ionic Gd. We used Gd(OAc)3 as a biological control to ensure that Gd(III) does not exhibit
activity in the system examined and to anticipate eventual replacement of nonradioactive
Gd(OAc)3 with radioactive Gd(OAc)3 for in vivo imaging.
The unreacted dendrimer surface in compounds 8, 9, and 12–16 contains amino groups,
which are known to be associated with cell toxicity (45). Therefore, we also produced
conjugates of carboxylic acid-containing PAMAM dendrimers by coupling an amine-
functionalized congener of UDPGA 3a to G2.5 (4) and G5.5 (6) PAMAM dendrimers to
form compounds 10 and 11. Compound 3a was further purified by a subsequent HPLC step
for subsequent biological testing. Compound 3a was reacted with PAMAM dendrimer G2.5
4 and G5.5 6 by EDC coupling in 0.1 M MES buffer under a nitrogen atmosphere and at pH
4.5 to 5.0 to form products 10 and 11, respectively. Each polymeric product was subjected to
dialysis in water to remove low MW impurities. Compounds 10 and 11 were analyzed by 1H
NMR and mass spectroscopy, which showed that the average number of monomers 3a in
compounds 10 and 11 was 17.3 and 29.9 per dendrimer, respectively.
Biological Activity
The activities of dendrimer conjugates were tested in human embryonic kidney (HEK293)
cells stably expressing the human P2Y14 receptor. Concentration effect curves were
generated as previously described (46) comparing the relative capacities of UDPG 1 and the
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denrimer conjugates to inhibit forskolin (30 μM)-stimulated cyclic AMP accumulation.
Neither compound 1 (46) nor any of the dendrimers tested (data not shown) exhibited
activity in wild-type HEK293 cells.
The control dendrimers 4 and 5 were inactive in this test system. In contrast, compound 9,
derived from the G3 dendrimer and containing free residual amino groups, was a very potent
agonist that exhibited an EC50 of 2.4 nM at the P2Y14 receptor (Figure 1). This potency was
approximately 100-fold greater than that of the native agonist UDPG 1, which had an EC50
of 261 nM. UDPGA 2 was approximately equipotent to 1 in this assay. The corresponding
dendrimer 8 (Figure 1), which had a lower degree of loading of the nucleotide on a G3
dendrimer, was considerably less potent than 9, but similar in potency to 1. Therefore, a
distinct multivalent effect occurs in these compounds.
Compounds 10 and 11, both of which were derived from half-integral dendrimers and
contain free residual carboxylate groups, were very potent at the P2Y14 receptor with EC50
values of 3.2 and 3.1 nM, respectively (Figure 2). The corresponding amine derivative 3a of
UDPGA, which also served as the synthetic precursor of conjugates 10 and 11, was
considerably less potent.
The higher molecular weight G6 dendrimer conjugate 12 was similar in relative composition
to the smaller conjugate 9, which had a high degree of loading of nucleotide. Compound 12
(EC50 = 0.8 nM) was significantly more potent than 9 (Figure 3). Both 9 and 12 contain
significant fractions (but less than 50%) of residual amino groups.
The G3 dendrimer conjugates 13 and 15 were equivalent to the precursor dendrimer
conjugate 12, except that they both contain covalently attached prosthetic groups in addition
to the nucleotide. Each of these dendrimers was essentially as potent as 9. The G3 dendrimer
conjugate 14, which had approximately two covalently attached AlexaFluor488 moieties,
was 17-fold less potent than the corresponding 9 but 7-fold more potent than compound 1.
However, when the DTPA conjugate 15 was complexed with gadolinium, the potency was
greatly reduced, to the level of 1, the native agonist.
Molecular Modeling
A molecular model of compound 3b docked to the human P2Y14 receptor recently was
constructed on the basis of the crystal structure of the human A2A adenosine receptor (15,
47). This model was utilized to build a complex of the P2Y14 receptor bound to a PAMAM
G3 dendrimer using the same approach as reported for the docking of a polyvalent
dendrimer–nucleoside conjugate to the human A2A adenosine receptor (48). In particular,
our published model of the conjugate of PAMAM (G3) with an A2A receptor agonist (2-[p-
(2-carboxyethyl)phenyl-ethylamino]-5′-N-ethylcarboxamidoadenosine, CGS21680) was
utilized to build a model of dendrimer–nucleotide conjugate 9, which was partially
substituted with nucleotide moieties. Initially, all fragments of the carboxylic acid
CGS21680 were removed from the model of PAMAM-CGS21680, and hydrogen atoms
were added to the remaining PAMAM structure. Twenty moieties of UDPGA 2 then were
coupled to randomly selected amino groups of the PAMAM chains. The remaining 12
unacylated chains of the dendrimer were substituted with protonated amino groups.
The model of 9 was minimized in the OPLS2005 force field. The Polak–Ribier conjugate
gradient (PRCG) minimization method with a maximum of 5000 iterations and with a
convergence threshold of 0.05 kJ · mol−1 · Å−1 was applied. One randomly selected
UDPGA moiety attached to the dendrimer then was removed from the PAMAM model, and
the UDPGA docked to the P2Y14 receptor was attached to the dendrimer. Thus, an initial
complex of 9 docked to the P2Y14 receptor was obtained. The orientation of a few UDPGA
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moieties was manually adjusted to avoid overlays with the amino acid residues of the P2Y14
receptor. The model was subjected to geometry optimization using the same protocol as
mentioned above. After minimization, the binding mode of the UDPGA moiety located
inside the P2Y14 receptor was found to be similar to the binding mode of 1 itself (15). The
ethylenediamine chain of PAMAM connected to the receptor-bound UDPGA moiety was
located between extracellular loops of P2Y14 receptor. In particular, the nucleotide moiety
was surrounded by Ile173 (EL2), and Leu175 (EL2), Arg274 (EL3), and Lys277 (7.35). In
addition, Lys277 formed an H-bond with the amide oxygen atom of the chain of PAMAM.
The molecular model of compound 9 docked in the human P2Y14 receptor (Figure 4)
showed that the nucleotide-substituted branches of the dendrimer extended far beyond the
dimensions of the receptor protein and thus would be available for multivalent docking to
receptor dimers and higher-order aggregates (49).
Discussion
A functionalized ethylenediamine-containing chain was incorporated in agonists of the
human P2Y14 receptor, and this chain provided a conjugation strategy for coupling
nucleoside agonists to PAMAM dendrimer carriers. Uridine-5′-diphosphoglucuronic acid
and its ethylenediamine adduct were suitable functionalized congeners (50) for coupling to
several generations (G2.5–6) of dendrimers (both terminal carboxy and amino) to modulate
potency of the intact conjugates. The observed biological activity of the dendrimer
conjugates was clearly P2Y14 receptor-dependent; the control dendrimers 4 and 5 lacking
nucleotides were inactive. A G3 PAMAM conjugate containing 20 bound nucleotide
moieties was 100-fold more potent than the native agonist 1. Larger dendrimer carriers and
those with greater loading favored higher potency as P2Y14 receptor agonists. All of the
dendrimer–nucleotide conjugates were full agonists at the receptor.
The molecular mechanism whereby these dendrimers exhibit increased activity relative to
the native cognate agonist UDPG is unclear. One possible explanation is that these
multivalent compounds may bridge multiple P2Y14 receptor binding sites simultaneously.
Molecular modeling has indicated this possibility for an analogous G3 PAMAM dendrimer
conjugate of an A2A adenosine receptor agonist (48). The dramatic enhancement in potency,
especially in the more heavily substituted dendrimer derivatives, is highly suggestive of a
multivalent effect. The ability to span multiple receptor binding sites would be further
promoted by the possible aggregation of dendrimer derivatives (56). Nanomolar and
subnanomolar potencies have been achieved, which are unprecedented for any monomeric
nucleotides acting at the P2Y14 receptor. Dendrimer conjugates 10 and 11, which are both
more than half substituted with nucleotide moieties, are more than 800-fold more potent
than a corresponding monomer, i.e., the ethylenediamine analogue 3a. Lower loading of the
same dendrimer with nucleotides resulted in a conjugate (compound 9) that exhibited
relatively lower potency. Variability of the potency depending on degree of loading will be
the subject of future systematic studies. Such studies also might benefit from quantification
of the relative activities of these compounds across a wide range of receptor expression
levels in the same cell system.
It is possible that conjugation to dendrimers might protect the nucleotides against enzymatic
degradation, but this is not the basis for the enhancement of potency in cAMP-inhibition
with the multivalent dendrimers. Our earlier studies (51) indicated that little metabolism of
extracellular 1 occurs under the conditions of these assays. Moreover, the concentration
effect curve of 1 for decreasing cyclic AMP levels is similar whether quantified at times of
<5 min or times up to 30 min.
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Dendrimers containing several different prosthetic groups also were synthesized. Dendrimer
conjugate 14, which is tagged with AlexaFluor488, potentially will be useful for receptor
visualization. Although the potency of 14 was 17-fold lower than that of the corresponding
dendrimer lacking the fluorescent group (i.e., 9), the EC50 of approximately 40 nM was
comparable to previously introduced fluorescent ligand probes for other GPCRs (52). A
similar approach in a previous study, using a fluorescent AlexaFluor488-tagged G3
PAMAM dendrimer, was used to detect the expression of the A3 adenosine receptor in
cultured cells (41). Gd(III) is a paramagnetic ion that is used for magnetic resonance
imaging (44). Dendrimer conjugate 15, which is tagged with the chelating group DTPA, is
substantially less potent as its Gd(III) complex, thus limiting the potential utility of this
derivative. The in vivo application of dendrimer conjugates is normally limited to i.p. or i.v.
injection, but novel approaches for gaining greater bioavailability of dendrimers by other
routes of administration have been discussed (53, 54).
In conclusion, we have identified a site on a nucleotide agonist of the P2Y14 receptor for
chemical tethering to a macromolecular carrier without losing the ability to activate the
receptor. Moreover, we have shown that the potency of the native ligand is greatly enhanced
in these multivalent ligands. These biologically active drug conjugates do not require
cleavage or cellular internalization for their action at the GPCR; in fact, these processes
would reduce activity. Covalent conjugation of P2Y14 receptor agonists to PAMAM
dendrimers qualitatively altered their pharmacological activity. Thus, potency was either
retained or dramatically enhanced in the multivalent dendrimer conjugates in comparison to
the monomeric P2Y14 receptor agonists, depending on size, degree of substitution, terminal
functionality, and attached prosthetic groups. The ability to modulate the potency of a given
GPCR ligand by the mode and stoichiometry of attachment to dendrimer carriers promises
to have general applicability to this therapeutically important class of receptor proteins.
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Refer to Web version on PubMed Central for supplementary material.
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Comparison of G3 dendrimer conjugates as agonists at the human P2Y14 receptor. The
capacities of UDPGA 2 (■) and the G3 dendrimer conjugates 5 (◆), 8 (○), and 9 (□) to
inhibit forskolin (30 μM) stimulated cyclic AMP accumulation were quantified in P2Y14–
HEK293 cells as described in Methods. Assays were carried out in triplicate, and all
experiments were repeated at least three times. Data were pooled and normalized using
forskolin-stimulated cyclic AMP accumulation as 100% and the phosphodiesterase inhibitor
IBMX alone as 0%.
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Comparison of G2.5 dendrimer conjugates as agonists at the human P2Y14 receptor. The
capacities of G2.5 dendrimer conjugates 3a (◊), 4 (◆), 8 (●), and 10 (○) to inhibit forskolin
(30 μM) stimulated cyclic AMP accumulation were quantified in P2Y14–HEK293 cells as
described in Methods. Assays were carried out in triplicate, and all experiments were
repeated at least three times. Data were pooled and normalized using forskolin-stimulated
cyclic AMP accumulation as 100% and IBMX alone as 0%.
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Comparison of larger dendrimer conjugates as agonists at the human P2Y14 receptor. The
capacities of UDPGA 2 (■), G3 dendrimer conjugate 9 (□), and G6 dendrimer conjugate 12
(○) to inhibit forskolin (30 μM)-stimulated cyclic AMP accumulation were quantified in
P2Y14–HEK293 cells as described in Methods. Assays were carried out in triplicate, and all
experiments were repeated at least three times. Data were pooled and normalized using
forskolin-stimulated cyclic AMP accumulation as 100% and IBMX alone as 0%.
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Molecular model of compound 9 docked in the human P2Y14 receptor, obtained after
docking to the receptor homology model built based on the crystal structure of the A2A
adenosine receptor (47). The receptor helices are colored by residue position: N-terminus in
red, TM 1 in orange, TM 2 in ochre, TM 3 in yellow, TM 4 in green, TM 5 in cyan, TM 6 in
blue, and TM 7 and C-terminus in purple.
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Scheme 1. Covalent Coupling of the Carboxylic Acid Functionalized Congener UDPGA 2 to
PAMAM Dendrimers of Integral Generations 3 and 6, by Carbodiimide Condensation with the
Surface Amino Groups of the Dendrimer
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Scheme 2. Multiple Functionalization of a Covalent Conjugate 9 of UDPGA 2 on a PAMAM G3
Dendrimer, For the Purpose of Fluorescent Detection (14), Avidin Binding (13), and Chelation
with Heavy Metal Gadolinium (16)
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Scheme 3. Synthesis of an Amine-Functionalized Congener UDPGA 3a and Its Covalent
Coupling to PAMAM Dendrimers of Half-Generations 2.5 and 5.5, by Carbodiimide
Condensation with the Surface Carboxylic Groups of the Dendrimer
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Chart 1. Structures of a Native Agonist of the P2Y14 Receptor 1 and a Carboxylic Acid
Derivative 2 Suitable for Covalent Coupling to Carriers while Preserving Biological Activity
Das et al. Page 21

























Das et al. Page 22
Table 1
In Vitro Pharmacological Data for Various Nucleotides and Their Complexes with
PAMAM Dendrimers
compound name/composition molecular weight (kD) EC50 at hP2Y14 receptor, nM
1 UDPG 0.61 261 ± 53
2 UDPGA 0.65 370 ± 70
3a UDPGA-ethylenediamine 0.82 2590 ± 1590
3b UDPGA-(N-Ac-ethylenediamine) 0.87 496 ± 67
4 G2.5 dendrimer 6.27 NEa
5 G3 dendrimer 6.91 NE
8 G3-(UDPGA)4.3 9.52 159 ± 14
9 G3-(UDPGA)20.1 19.11 2.4 ± 0.1
10 G2.5-(UDPGA-ethylenediamine)17.3 18.48 3.2 ± 1.4
11 G5.5-(UDPGA-ethylenediamine)29.9 71.65 3.1 ±0.8
12 G6-(UDPGA)147 147.31 0.8 ± 0.4
13 G3-(UDPGA)20.1-(Biotin)4.9 20.77 3.4 ± 0.8
14 G3-(UDPGA)20.1-(AlexaFluor488)2.3 20.77 39.8 ± 7.4
15 G3-(UDPGA)20.1-(DTPA)4.5 21.55 4.1 ± 1.2
16 G3-(UDPGA)20.1-(DTPA-Gd(III))4.5 22.31 421 ± 104
a
NE, no effect.
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